What are the primary‑care clinical practice guidelines for diagnosing, managing, and preventing dengue in adult and pediatric Filipino patients?

Clinical Practice Guidelines for Dengue in Filipino Primary Care

Diagnostic Approach

For Filipino patients presenting with suspected dengue in primary care, diagnosis should be based on clinical criteria combined with timing-appropriate laboratory testing, recognizing that the disease characteristically progresses through three distinct phases: febrile, critical, and recovery. 1

Clinical Case Definition

• Suspect dengue in any patient with fever plus one or more of the following: nausea, vomiting, rash, headache, retro-orbital pain, myalgia, arthralgia, positive tourniquet test, leukopenia, or warning signs 2
• The disease affects both children and adults equally in the Philippines, with peak incidence in the 15-19 year age group, though the median age is shifting upward 3
• More than 90% of cases are mild, but severe dengue (with shock and/or mucosal hemorrhages) carries 1-5% mortality 4

Laboratory Testing Strategy

Specimens collected ≤7 days after symptom onset:

• Perform nucleic acid amplification testing (NAAT) on serum as the primary diagnostic test 2, 5
• NS1 antigen testing can be used as an alternative or adjunct to NAAT 2, 5
• If NS1 is negative but IgM/IgG are positive, perform confirmatory NAAT because antibodies may not yet be fully developed 5
• When all markers (NS1, IgM, IgG) are negative, dengue cannot be excluded—NAAT should be performed if available 5

Specimens collected >7 days after symptom onset:

• IgM antibody testing becomes the primary diagnostic modality 2, 5
• A positive IgM (with or without IgG) strongly suggests recent dengue infection 5
• When both IgM and IgG are negative in samples taken 7 days to 12 weeks after onset, recent dengue is ruled out and alternative diagnoses should be pursued 5

Managing Indeterminate Results

• Trace-positive (indeterminate) IgM requires repeat testing on the same specimen or confirmatory plaque reduction neutralization testing (PRNT) 6
• Indeterminate results may represent early antibody response before full seroconversion 6
• A PRNT titer ≥10 for dengue with titer <10 for Zika/other flaviviruses confirms recent dengue infection 5, 6

Risk Stratification and Management

Phase-Based Clinical Monitoring

Febrile Phase (Days 1-3):

• Monitor for warning signs: abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy/restlessness, liver enlargement >2 cm, rising hematocrit with rapid platelet decline 1, 4
• Most patients can be managed as outpatients with close monitoring 4

Critical Phase (Days 4-7):

• This is when plasma leakage, shock, and hemorrhage occur 1, 4
• Patients with warning signs or risk factors require hospital admission 4
• The key to preventing mortality is adequate volume replacement during this phase 4

Recovery Phase (After Day 7):

• Reabsorption of extravasated fluid occurs 4
• Monitor for fluid overload complications 1

Treatment Principles

Outpatient Management:

• Symptomatic treatment only—no specific antiviral therapy is available 4
• Adequate oral hydration 1, 4
• Antipyretics (paracetamol/acetaminophen)—avoid NSAIDs and aspirin due to bleeding risk 1
• Daily clinical reassessment for warning signs 1

Inpatient Management:

• Intravenous fluid resuscitation is the cornerstone of severe dengue management 4
• For patients with hemorrhage, transfuse blood products as needed 4
• Monitor hematocrit, platelet count, and vital signs closely 1, 4

Special Population: Pregnant Women

• Dengue increases risk for maternal death, hemorrhage, preeclampsia, eclampsia, and vertical transmission during the peripartum period 2
• Perform both NAAT and IgM testing on serum, plus NAAT on urine to assess for possible Zika co-infection 5
• Test for Zika within ≤12 weeks of symptom onset for optimal sensitivity 5

Age-Specific Considerations

• Older adults (≥65 years) face increased risks of severe disease, prolonged hospitalization, and higher mortality due to immune senescence and multimorbidity 7
• Pediatric and adult patients show similar initial signs and symptoms, though hematocrit and hemoglobin levels differ significantly 3
• The majority of Philippine cases (92%) represent secondary dengue infection, which carries higher risk of severe disease 3

Prevention Strategies

Vector Control

• Community participation is crucial—social support strongly influences preventive behaviors (OR 19.81; 95% CI 8.53-46.03) 8
• Eliminate mosquito breeding sites through source reduction 1, 8
• Use of insecticide-treated materials and personal protective measures 1

Vaccination

• Current vaccines should only be administered after documented initial infection due to safety concerns in seronegative individuals 4
• Vaccine efficacy and safety data in older adults remain limited 7
• Transparent, culturally tailored communication is needed to address vaccine hesitancy 8

Personal Protection

• Meticulous avoidance of mosquito bites through repellents, protective clothing, and bed nets 4
• Particularly important during daytime hours when Aedes mosquitoes are most active 4

Differential Diagnosis Considerations

• Rule out chikungunya, Zika, malaria, rubella, measles, hepatitis A, parvovirus, adenovirus, enterovirus, leptospirosis, rickettsiosis, and group A streptococcal infections 2
• Cross-reactivity with other flaviviruses (Zika, yellow fever, Japanese encephalitis) is common in endemic regions and can produce false-positive IgM results 6
• Interpretation must incorporate local circulation patterns of dengue serotypes and co-circulating flaviviruses 5, 6

Key Pitfalls to Avoid

• Do not rely on a single negative rapid test in the first week—NAAT is required to exclude dengue 5, 6
• Do not assume IgM positivity indicates recent infection—IgM can persist for months after infection 5, 6
• Do not discharge patients during the critical phase (days 4-7) without ensuring adequate follow-up 1, 4
• Do not use NSAIDs or aspirin for fever control due to hemorrhage risk 1